Cargando…
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Altho...
Autores principales: | Al-Khadairi, Ghaneya, Decock, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678383/ https://www.ncbi.nlm.nih.gov/pubmed/31311081 http://dx.doi.org/10.3390/cancers11070984 |
Ejemplares similares
-
Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
por: Naik, Adviti, et al.
Publicado: (2021) -
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019) -
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021) -
The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
por: Xu, Yichi, et al.
Publicado: (2020) -
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)